Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
97.5 USD | +0.42% | +0.12% | -3.54% |
Apr. 29 | Novartis target Morphosys multiplies losses - takeover schedule stands | DP |
Apr. 29 | Morphosys says takeover by Novartis on course after report of drug safety concern | RE |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's enterprise value to sales, at 3.98 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.54% | 199B | - | ||
+34.66% | 664B | C+ | ||
+28.58% | 567B | B | ||
-6.79% | 354B | C+ | ||
+19.68% | 330B | B- | ||
+3.47% | 286B | C+ | ||
+13.68% | 234B | B+ | ||
-10.14% | 196B | A+ | ||
-5.23% | 148B | C+ | ||
-10.52% | 145B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NOVN Stock
- NVS Stock
- Ratings Novartis AG